It’s on Saturday that the Journal of the American Heart Association published the conclusive results from a study directed by Dr. Éric Thorin of the Montreal Heart Institute (MHI), which suggests for the first time that a blood protein contributes to the early development of atherosclerosis.
Dr. Denis Roy, Executive Director of the Montreal Heart Institute (MHI), along with Dr. Jean-Claude Tardif, Director of the MHI Research Centre, are pleased to announce the appointment of Mr. Denis Bilodeau to the position of Director, Strategy and Innovation of the MHI Research Centre, as of April 15, 2013.
The Research Centre of the Montreal Heart Institute (MHI) achieved incredible results in the prestigious 2012 Genomics and Personalized Health national competition funded by Genome Canada and the CIHR. Dr. Jean-Claude Tardif and Dr. John D. Rioux from the MHI each received $10 million for research into personalized medicine.
A single dose of an investigational anti-inflammatory drug called inclacumab considerably reduces damage to heart muscle during angioplasty (the opening of a blocked artery), according to a recent international clinical trial spearheaded by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, affiliated to the University of Montreal.
The Montreal Heart Institute (MHI) has become the first hospital in North America where patients can benefit from a GPS system that lets cardiologists accurately navigate the heart during procedures to treat cardiac rhythm disorders. Developed by St. Jude Medical, MediGuide Technology considerably reduces radiation exposure by producing a full three-dimensional (3D) image of the heart from pre-recorded X-rays.
The Montreal Heart Institute has just been designated as a Center of Excellence by Abbott Vascular for the percutaneous treatment of mitral valve failure with their MitraClip system. The MHI has therefore become a reference centre for this procedure for all hospitals across Canada and many other hospitals in North America.
